Prosecution Insights
Last updated: October 26, 2026

Kyle Gregory Nottingham, USPTO Patent Examiner

Listed by the USPTO as NOTTINGHAM, KYLE GREGORY

Tech Center 1700 • Art Units: 1621 1797

This examiner grants 62% of resolved cases

Analysis

NOTTINGHAM, KYLE GREGORY is assigned to tech center 1700 and art unit 1621. The profile includes 115 resolved cases, an allowance rate of 61.7%, and a median of 1202 days to allowance. The interview lift is 31.9%, showing a strong relationship between interviews and allowance outcomes in the available record. The smaller case volume calls for caution, but the interview measure supports giving examiner discussions a prominent place in prosecution planning.

The listed companies are Boehringer Ingelheim International GmbH, Eli Lilly and Company, and Prilenia Neurotherapeutics Ltd. The listed firms are Biospark Intellectual Property Law, BUCHANAN, INGERSOLL & ROONEY PC, and CARTER, DELUCA & FARRELL LLP. Counsel may prepare interviews around concrete claim distinctions and supporting technical explanations, while maintaining fallback amendments for a prosecution process with a median allowance timing of 1202 days.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

61.7%
Allow Rate
-3.3% vs TC avg
165
Total Applications
+31.9%
Interview Lift
1202
Avg Prosecution Days
Based on 115 resolved cases, 2023–2026

Rejection Statute Breakdown

2.3%
§101 Eligibility
17.7%
§102 Novelty
33.8%
§103 Obviousness
27.2%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18789814 PIPERIDINYLPYRIDINYLCARBONITRILE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN Non-Final OA Boehringer Ingelheim International GmbH
18721824 COMPOUNDS FOR TREATMENT OF CANCER Non-Final OA THE JOHNS HOPKINS UNIVERSITY
18707089 N,N-DIMETHYLAMPHETAMINE ANALOGS FOR TREATING BRAIN DISORDERS Non-Final OA The Regents of the University of California
18549864 MTA-Cooperative PRMT5 Inhibitors Non-Final OA Mirati Therapeutics, Inc.
17850720 COMPOSITIONS AND METHODS FOR OPTOCHEMICAL CONTROL OF MTOR SIGNALING AND MTOR-DEPENDENT AUTOPHAGY Final Rejection The University of Hong Kong

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Kyle Gregory Nottingham's allowance rate?

61.7% of resolved applications examined by Kyle Gregory Nottingham were allowed (115 resolved cases), compared with 46.0% across Art Unit 1621 over the last five years.

Does an interview help with examiner Kyle Gregory Nottingham?

This examiner's interview lift is +31.9 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Kyle Gregory Nottingham take to allow a patent?

Applications allowed by Kyle Gregory Nottingham took 1,202 days on average from filing to allowance.

Which art unit does examiner Kyle Gregory Nottingham work in?

Kyle Gregory Nottingham examines applications in Art Unit 1621 in Tech Center 1700 (Chemistry & Materials).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month